Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel 1.5 mg
Information source: Bayer
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Contraceptives, Postcoital
Intervention: Levonorgestrel Emergency Pill (BAY86-5028) (Drug); Postinor 2 (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Bayer Official(s) and/or principal investigator(s): Bayer Study Director, Study Director, Affiliation: Bayer
Summary
A single dose, two treatments (Postinor-2 and Opxion), two periods, two sequences,
crossover, randomized, prospective design was chosen with a washout of 14 days between the
two study periods. Treatment groups are balanced with the same number of male healthy
volunteers who were randomly assigned to the study drug administration sequences.
Clinical Details
Official title: Open-label, Randomized, Crossover Study to Prove the Bioequivalence Between Opxion® (Levonorgestrel 1.5 mg Coated Tablet From Bayer de Mexico) and Postinor 2® (Levonorgestrel 1.5 mg Tablet From Biofarma Natural CMD) in Healthy Volunteers
Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label
Primary outcome: Least square estimator of average maximum plasmatic concentration (log transformed)Least square estimator of area under the pharmacokinetic curve (log transformed)
Secondary outcome: Time at which maximum concentration is reachedArea under the pharmacokinetic curve from time=0 to last blood sample Half life of plasmatic concentration of study drug Clearance constant of plasmatic concentration of study drug Adverse events collection
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Healthy male volunteers age between 18 and 55 years old with normal vital signs,
electrocardiogram (ECG), blood chemistry, liver function profile and urinalysis.
Exclusion Criteria:
- History of illnesses or any organic abnormalities that could affect the results of
the study.
- History of tobacco or alcohol abuse or regular use of recreational or therapeutic
drugs.
- Subjects that have taken any medication within 14 days or that are in an elimination
period of less than 7 half-lives (whichever is longest) before study startup.
Locations and Contacts
Morelia, Michoacán 58256, Mexico
Additional Information
Click here and search for drug information provided by the FDA. Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
Starting date: September 2009
Last updated: April 1, 2014
|